Analytical Data
-
Gene name
PAMP
- Application
-
Alternative Names
FTSH; MEG4; YME1L1; YME1L; ATP-dependent metalloprotease FtsH1; YME1 Like Protein 1; ATP-dependent zinc metalloprotease YME1L1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O88967
-
Expression Region
Met1~Leu237
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PAMP (Pathogen-Associated Molecular Patterns) recombinant proteins are crucial in immunology and microbiology research as they play a significant role in pathogen recognition and the subsequent immune response. These proteins are derived from various pathogens, including bacteria, viruses, and fungi, and are recognized by pattern recognition receptors (PRRs) in the host's immune system. The study of PAMPs has gained importance in recent years due to the rise of infectious diseases and the need for effective vaccines and therapeutics. By using recombinant DNA technology, researchers can produce these proteins in large quantities and with high purity, allowing for detailed studies of their role in immunity. This includes understanding how they activate signaling pathways, induce cytokine release, and influence adaptive immunity. Furthermore, PAMPs have been instrumental in the development of adjuvants, enhancing vaccine efficacy by mimicking natural infection patterns. Ongoing research focuses on elucidating the mechanisms of PAMP-induced immune responses and their potential applications in clinical settings, such as improving vaccine design and developing novel treatments for infectious diseases and immune disorders. Overall, the exploration of PAMP recombinant proteins holds promise for advancing our understanding of host-pathogen interactions and enhancing public health strategies.
